Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × revumenib × 1 year × Clear all

Status

Recruiting 10 Not yet recruiting 1 No longer available 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Leukemia 1

Interventions

Suspensions 2 Powders 2 zanidatamab 1 trametinib 1 taletrectinib 1 ruxolitinib 1 revumenib 1 patritumab deruxtecan 1 omburtamab I-131 1 omaveloxolone 1 leronlimab 1 derazantinib 1 dabrafenib 1 capmatinib 1 asparaginase erwinia chrysanthemi recombinant 1 apalutamide 1 Standard of Care 1 Paclitaxel 1 Nivolumab 1 HMPL-013 1 Everolimus 1 Docetaxel 1 Asparaginase 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡